Optimal First-Line Therapy Selection for Metastatic Colorectal Cancer (IASGO 2026) - Sep 23, 2026 - Abstract #SY12-3; Pres time: Sep 9, 2026; 02:40 PM - 04:10 PM; "For most patients with pMMR/MSS tumors, a fluoropyrimidine-based doublet remains the backbone.FOLFOX and FOLFIRI provide similar efficacy, so the choice should reflect comorbidities andanticipated toxicity: neuropathy and thrombocytopenia are more relevant with oxaliplatin, whereasgastrointestinal toxicity and alopecia are more common with irinotecan...In left-sided RAS/BRAF wild-type mCRC,cetuximab plus FOLFOX or FOLFIRI is an appropriate first-line strategy...Three clinical cases illustrate this framework: a left-sided RAS/BRAF wild-type MSS tumor treated withcetuximab-FOLFIRI; a right-sided MSS tumor treated with bevacizumab-FOLFOX; and an MSI-H cecalcancer achieving a deep response to pembrolizumab. The central message is that first-line therapyshould follow a structured sequence: profile the tumor, define treatment goals and fitness, match thebiologic strategy, and apply current Korean reimbursement criteria while preserving effective optionsfor later lines."
Clinical • IO biomarker • Metastases • Alopecia • Colorectal Cancer • Immunology • Microsatellite Instability • Oncology • Solid Tumor • Thrombocytopenia • BRAF • KRAS • MSI • NRAS • POLD1 • POLE
|